CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
Topical Avastin 1%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00559936
NCT00559936Phase 1Completed
CompareCT.gov

Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization

Massachusetts Eye and Ear Infirmary·interventional·Posted Nov 16, 2007·Updated Apr 29, 2022

In Brief

A Phase 1 clinical trial evaluating Topical Avastin 1% for Corneal Neovascularization. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the effectiveness and safety of Topical Bevacizumab (Avastin) for treatment of corneal neovascularization.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCorneal Neovascularization
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 16, 2007
Enrollment StartFeb 1, 2007
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 18.6 years ago

Interventions

Topical Avastin 1%drug

Avastin (bevacizumab) 1%